Premium
Selective Targeting of Human Alloresponsive CD8 + Effector Memory T Cells Based on CD2 Expression
Author(s) -
Lo D. J.,
Weaver T. A.,
Stempora L.,
Mehta A. K.,
Ford M. L.,
Larsen C. P.,
Kirk A. D.
Publication year - 2011
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2010.03317.x
Subject(s) - belatacept , cytotoxic t cell , cd28 , immunology , granzyme b , cd8 , effector , medicine , t cell , cancer research , biology , transplantation , immune system , in vitro , kidney transplantation , biochemistry , kidney transplant
Costimulation blockade (CoB), specifically CD28/B7 inhibition with belatacept, is an emerging clinical replacement for calcineurin inhibitor‐based immunosuppression in allotransplantation. However, there is accumulating evidence that belatacept incompletely controls alloreactive T cells that lose CD28 expression during terminal differentiation. We have recently shown that the CD2‐specific fusion protein alefacept controls costimulation blockade‐resistant allograft rejection in nonhuman primates. Here, we have investigated the relationship between human alloreactive T cells, costimulation blockade sensitivity and CD2 expression to determine whether these findings warrant potential clinical translation. Using polychromatic flow cytometry, we found that CD8 + effector memory T cells are distinctly high CD2 and low CD28 expressors. Alloresponsive CD8 + CD2 hi CD28 − T cells contained the highest proportion of cells with polyfunctional cytokine (IFNγ, TNF and IL‐2) and cytotoxic effector molecule (CD107a and granzyme B) expression capability. Treatment with belatacept in vitro incompletely attenuated allospecific proliferation, but alefacept inhibited belatacept‐resistant proliferation. These results suggest that highly alloreactive effector T cells exert their late stage functions without reliance on ongoing CD28/B7 costimulation. Their high CD2 expression increases their susceptibility to alefacept. These studies combined with in vivo nonhuman primate data provide a rationale for translation of an immunosuppression regimen pairing alefacept and belatacept to human renal transplantation.